SEC Form 4 · accession 0001179110-19-001321
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Dimitrios Chondros
Officer — SVP, Chief Medical Officer
Period of report
Feb 3, 2019
Accepted (ET)
Feb 5, 2019 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 3, 2019 | F | 2,503 | $16.12 | D | 31,599 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported disposition of 2,503 shares represents the shares that were withheld by the issuer as payment for minimum statutory obligations due upon vesting of 6,165 restricted stock award shares.